Xtant Medical Holdings Inc
$ 0.57
-2.98%
24 Feb - close price
- Market Cap 79,816,000 USD
- Current Price $ 0.57
- High / Low $ 0.59 / 0.56
- Stock P/E 57.01
- Book Value 0.36
- EPS 0.01
- Next Earning Report 2026-03-05
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.04 %
- ROE 0.04 %
- 52 Week High 0.95
- 52 Week Low 0.34
About
Xtant Medical Holdings, Inc. develops, manufactures, and markets regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. The company is headquartered in Belgrade, Montana.
Analyst Target Price
$1.50
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-10 | 2025-08-12 | 2025-05-12 | 2025-03-31 | 2024-11-07 | 2024-08-08 | 2024-04-01 | 2024-02-13 | 2023-11-09 | 2023-08-01 | 2023-05-04 | 2023-03-07 |
| Reported EPS | 0.01 | 0.02 | 0.2791 | -0.0134 | -0.04 | -0.03 | -0.03 | -0.03 | 0.07 | -0.02 | -0.02 | -0.02 |
| Estimated EPS | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 | -0.02 | -0.03 | -0.02 |
| Surprise | 0.02 | 0.03 | 0.2891 | 0.0066 | -0.02 | -0.01 | -0.01 | -0.01 | 0.09 | 0 | 0.01 | 0 |
| Surprise Percentage | 200% | 300% | 2891% | 33% | -100% | -50% | -50% | -50% | 450% | 0% | 33.3333% | 0% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-05 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: XTNT
2026-02-16 16:57:51
Xtant Medical Holdings, Inc. (XTNT) experienced a 16.4% decrease in short interest in January, totaling 20,671 shares. Institutional investors, including Nantahala Capital Management LLC and Renaissance Technologies LLC, have significantly increased their stakes in the company, now collectively owning 69.33% of the stock. Despite a reduced price target from BTIG Research to $1.50, analysts maintain a "Buy" rating, implying substantial upside from its current trading price of around $0.58.
2026-02-02 04:58:56
Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) experienced a significant 25.3% decrease in short interest during January, with total short interest falling to 24,740 shares. This translates to a very low days-to-cover ratio of 0.1 days, indicating minimal bearish sentiment. Despite a price target reduction by BTIG Research, the company maintains a "Buy" rating, and institutional ownership remains high at 69.33%.
2026-01-25 11:29:14
This article reports on Xtant Medical's strong Q3 2025 results. It highlights the company's financial performance and key achievements during the quarter.
2026-01-22 09:57:33
Xtant Medical's (NYSEAMERICAN:XTNT) stock price briefly rose above its 200-day moving average of $0.68, trading as high as $0.6870 before settling at $0.63. Despite a recent reduction in price target by BTIG Research from $2.00 to $1.50, the consensus analyst rating remains "Buy" with a target of $1.50. The company reported quarterly EPS of $0.01, exceeding estimates, though revenue of $27.77 million missed the consensus.
2026-01-16 21:29:25
Xtant Medical Holdings has amended agreements with Companion Spine, extending a note's maturity date and adjusting payment timing. The note's maturity moved from January 15 to January 31, 2026, and the payment timing for a $1.742 million purchase price adjustment related to Paradigm Spine was also moved to January 31, 2026. These changes were detailed in an SEC filing on January 16, 2026.
2026-01-02 05:08:50
Xtant Medical (NYSEAMERICAN:XTNT) recently saw its share price cross above its 200-day moving average, trading at $0.7840 with a volume of 139,917 shares. Despite a lowered price target from BTIG Research, the company maintains a "Buy" rating from analysts with an average price target of $1.50. Quarterly results were mixed, with an EPS beat but a revenue miss, and hedge funds have been actively adjusting their stakes in the company.
